Clinical trial · Interventional
Safety and Exploratory Efficacy of Kanglaite Injection in Non Small Cell Lung Cancer
An Open Label Safety and Exploratory Efficacy Study of Kanglaite Injection in Patients Having Progressive Stage IV NSCLC Who Are Not Candidates for Other Anti-cancer Treatment
NCT01640730CI-TRIAL-00013483terminatedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): poor enrollment
Summary
Brief summary (as posted)
This study is for patients with advanced non small cell lung cancer that has progressed despite standard of care. The purpose of the study is to see if Kanglaite injection has any effect on survival.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Stage IV NSCLC | Lung Non-Small Cell Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Kanglaite Injection | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Kanglaite injection
- interventionNames
- Drug: Kanglaite Injection
Primary outcomes (1)
- measure
- Overall Survival
- timeFrame
- from date of enrollment until date of death from any cause assessed up to 12 months
Secondary outcomes (2)
- measure
- Bioimpedance Phase Angle
- timeFrame
- measured each month up to one year
- measure
- Palliation Response Measure
- timeFrame
- each month up to one year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * confirmed (within last 3 months)progressive Stage IV NSCLC * estimated life span of 3 months * phase angle of at least 5 as measured by bioimpedance Exclusion Criteria: * currently taking a lipid lowering medications * has an imminently life threatening condition * has pre-existing liver disease * known allergy to soybeans * uncontrolled diabetes or uncontrolled disturbance of lipid metabolism * pregnant or lactating * has a pacemaker or other implantable electronic medical device
References
Publications (0)
Data not yet available
No reference posted for this study.